Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
J. Brent Richards and colleagues assess whether genetically predicted vitamin D levels associate with risk of multiple sclerosis.
Vyšlo v časopise:
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med 12(8): e32767. doi:10.1371/journal.pmed.1001866
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001866
Souhrn
J. Brent Richards and colleagues assess whether genetically predicted vitamin D levels associate with risk of multiple sclerosis.
Zdroje
1. Ramagopalan SV, Sadovnick AD. Epidemiology of multiple sclerosis. Neurol Clin. 2011;29:207–217. doi: 10.1016/j.ncl.2010.12.010 21439437
2. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:1132–1141. doi: 10.1136/jnnp.2011.240432 21478203
3. Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology. 1999;53:1711–1718. doi: 10.1212/WNL.53.8.1711 10563617
4. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268–277. doi: 10.1016/S1474-4422(08)70042-5 18275928
5. Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–65. doi: 10.1212/WNL.63.5.939 14718698
6. Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67:618–624. doi: 10.1002/ana.21972 20437559
7. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–240. doi: 10.1002/ana.23591 22926855
8. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33:456–492. doi: 10.1210/er.2012-1000 22596255
9. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 2013;19:1571–1579. doi: 10.1177/1352458513489756 23698130
10. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch H-M, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74:1852–1859. doi: 10.1212/WNL.0b013e3181e1cec2 20427749
11. Kimball SM, Ursell MR, O’Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86:645–651. 17823429
12. Wright S, Yadav V, Bever CJ, Bowen J, Bowling A, Weinstock-Guttman B, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;83:1484–1486. doi: 10.1212/01.wnl.0000455935.13606.91
13. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88:1519–1527. doi: 10.3945/ajcn.2008.26182 19064511
14. Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr. 2008;88:558S–564S. 18689402
15. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–1163. 17886233
16. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580. doi: 10.1016/S0140-6736(12)60312-2 22607825
17. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–1908. doi: 10.1056/NEJMoa0707402 18971492
18. Cohen JC, Boerwinkle E, Mosley THJ, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. doi: 10.1056/NEJMoa054013 16554528
19. Wang TJ, Zhang F, Richards JB, Kestenbaum B, Van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180–188. doi: 10.1016/S0140-6736(10)60588-0 20541252
20. Faye LL, Sun L, Dimitromanolakis A, Bull SB. A flexible genome-wide bootstrap method that accounts for ranking and threshold-selection bias in GWAS interpretation and replication study design. Stat Med. 2011;30:1898–1912. doi: 10.1002/sim.4228 21538984
21. International Multiple Sclerosis Genetic Consortium, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353–1360. doi: 10.1038/ng.2770 24076602
22. Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703 16283615
23. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127. 11456302
24. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231. doi: 10.1002/ana.410130302 6847134
25. International Multiple Sclerosis Genetic Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214–219. doi: 10.1038/nature10251 21833088
26. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56–65. doi: 10.1038/nature11632 23128226
27. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89–R98. doi: 10.1093/hmg/ddu328 25064373
28. Berry DJ, Vimaleswaran KS, Whittaker JC, Hingorani AD, Hyppönen E. Evaluation of genetic markers as instruments for Mendelian randomization studies on vitamin D. PLoS ONE. 2012;7:e37465. doi: 10.1371/journal.pone.0037465 22629401
29. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–665. doi: 10.1002/gepi.21758 24114802
30. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–109. doi: 10.1038/nature10405 21909115
31. Dastani Z, Hivert M-FF, Timpson NJ, Perry JRB, Yuan X, Scott RA., et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012;8:e1002607. doi: 10.1371/journal.pgen.1002607 22479202
32. Patsopoulos NA, Evangelou E, Ioannidis JPA. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37:1148–1157. doi: 10.1093/ije/dyn065 18424475
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. 12958120
34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. 12111919
35. Ross AC. Dietary reference intakes for calcium and vitamin D. Washington (District of Columbia): Institute of Medicine. Available: http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. Accessed 22 July 2015.
36. Dastani Z, Li R, Richards B. Genetic regulation of vitamin D levels. Calcif Tissue Int. 2013;92:106–117. doi: 10.1007/s00223-012-9660-z 23114382
37. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103:239–251. 9916136
38. Bikle DD, Siiteri PK, Ryzen E, Haddad JG. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab. 1985;61:969–975. doi: 10.1210/jcem-61-5-969 3840175
39. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol. 2002;9:131–136. doi: 10.1038/nsb754 11799400
40. Shinkyo R, Sakaki T, Kamakura M, Ohta M, Inouye K. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun. 2004;324:451–457. doi: 10.1016/j.bbrc.2004.09.073 15465040
41. Kongsbak M, von Essen MR, Levring TB, Schjerling P, Woetmann A, Odum N, et al. Vitamin D-binding protein controls T cell responses to vitamin D. BMC Immunol. 2014;15:35. doi: 10.1186/s12865-014-0035-2 25230725
42. Moon M, Song H, Hong HJ, Nam DW, Cha M-Y, Oh MS, et al. Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology. Cell Death Differ. 2013;20:630–638. doi: 10.1038/cdd.2012.161 23257976
43. Rinaldi AO, Sanseverino I, Purificato C, Cortese A, Mechelli R, Francisci S, et al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins (Basel). 2015;7:129–137. doi: 10.3390/toxins7010129
44. Yang M, Qin Z, Zhu Y, Li Y, Qin Y, Jing Y, et al. Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression. Mol Neurobiol. 2013;47:946–956. doi: 10.1007/s12035-012-8387-1 23339019
45. Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, et al. Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: results from a multi-center study. J Steroid Biochem Mol Biol. 2014;143:424–433. doi: 10.1016/j.jsbmb.2014.06.007 24950029
46. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–1283. doi: 10.1038/ng.2797 24097068
47. Van Luijn MM, Kreft KL, Jongsma ML, Mes SW, Wierenga-Wolf AF, van Meurs M, et al. Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis. Brain. 2015;138:1531–1547. doi: 10.1093/brain/awv080 25823473
48. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton S-M, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5:e1000369. doi: 10.1371/journal.pgen.1000369 19197344
49. O’Connell K, Kelly S, Kinsella K, Jordan S, Kenny O, Murphy D, et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials. 2013;14:272. doi: 10.1186/1745-6215-14-272 23981773
50. Thouvenot E, Suehs CM. Efficacy of cholecalciferol (vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS). ClinicalTrials.gov. Available: https://clinicaltrials.gov/ct2/show/NCT01817166?term=vitamin+d+multiple+sclerosis&rank=13. Accessed 22 July 2015.
51. Mokry LE, Ahmad O, Forgetta V, Thanassoulis G, Richards JB. Mendelian randomisation applied to drug development in cardiovascular disease: a review. J Med Genet. 2015;52:71–79. doi: 10.1136/jmedgenet-2014-102438 25515070
52. Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. 12689998
53. Leong A, Rehman W, Dastani Z, Greenwood C, Timpson N, Langsetmo L, et al. The causal effect of vitamin D binding protein (DBP) levels on calcemic and cardiometabolic diseases: a Mendelian randomization study. PLoS Med. 2014;11:e1001751. doi: 10.1371/journal.pmed.1001751 25350643
54. Ye Z, Sharp SJ, Burgess S, Scott RA, Imamura F, Consortium I, et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2015;3:35–42. doi: 10.1016/s2213-8587(14)70184-6 25281353
55. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes. 2011;60:1624–1631. doi: 10.2337/db10-1656 21441443
56. Vimaleswaran KS, Cavadino A, Berry DJ, LifeLines Cohort Study Investigators, Jorde R, Dieffenbach AK, et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;2:719–729. doi: 10.1016/s2213-8587(14)70113-5 24974252
57. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;10:e1001383. doi: 10.1371/journal.pmed.1001383 23393431
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2015 Číslo 8
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- The Polypill: From Promise to Pragmatism
- Open Access to a High-Quality, Impartial, Point-of-Care Medical Summary Would Save Lives: Why Does It Not Exist?
- The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study
- Retained in HIV Care But Not on Antiretroviral Treatment: A Qualitative Patient-Provider Dyadic Study